JP2023549537A5 - - Google Patents

Info

Publication number
JP2023549537A5
JP2023549537A5 JP2023528957A JP2023528957A JP2023549537A5 JP 2023549537 A5 JP2023549537 A5 JP 2023549537A5 JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023549537 A5 JP2023549537 A5 JP 2023549537A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059444 external-priority patent/WO2022104236A2/en
Publication of JP2023549537A publication Critical patent/JP2023549537A/ja
Publication of JP2023549537A5 publication Critical patent/JP2023549537A5/ja
Pending legal-status Critical Current

Links

JP2023528957A 2020-11-16 2021-11-16 多重特異性抗体およびその使用方法 Pending JP2023549537A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114479P 2020-11-16 2020-11-16
US63/114,479 2020-11-16
US202163237526P 2021-08-26 2021-08-26
US63/237,526 2021-08-26
PCT/US2021/059444 WO2022104236A2 (en) 2020-11-16 2021-11-16 Multispecific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549537A JP2023549537A (ja) 2023-11-27
JP2023549537A5 true JP2023549537A5 (enExample) 2024-11-20

Family

ID=81601772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528957A Pending JP2023549537A (ja) 2020-11-16 2021-11-16 多重特異性抗体およびその使用方法

Country Status (4)

Country Link
US (1) US20230399408A1 (enExample)
EP (1) EP4243938A4 (enExample)
JP (1) JP2023549537A (enExample)
WO (1) WO2022104236A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525275A (ja) 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
CN119948063A (zh) * 2022-06-23 2025-05-06 信达生物制药(苏州)有限公司 结合egfr和b7-h3的双特异性抗体
CA3256857A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. EGFR/MET ANTIBODIES AND THEIR USES
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 ｃ－Ｍｅｔを標的とする多重特異性抗体
AU2024315062A1 (en) * 2023-07-28 2026-03-12 Tigatx, Inc. Engineered iga antibodies and methods of use
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
WO2025042806A2 (en) * 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
CN120271706A (zh) 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
WO2026021476A1 (en) * 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
WO2026145588A1 (en) * 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
LT3466972T (lt) * 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
RS66708B9 (sr) * 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
WO2020172528A1 (en) * 2019-02-22 2020-08-27 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
JP2022525275A (ja) * 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
MY208668A (en) * 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP7844558B2 (ja) リンパ球における阻害経路の中和
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
JP2022101693A5 (enExample)
JP2021528973A5 (enExample)
JP2024001073A5 (enExample)
JP2019527553A5 (enExample)
JP2017529838A5 (enExample)
JP2017535257A5 (enExample)
JP2023516004A5 (enExample)
JP2022553922A5 (enExample)
JP2024532489A5 (enExample)
JP2023548529A5 (enExample)
JP2022545741A5 (enExample)
JP7755062B2 (ja) 新規抗ｌ１ｃａｍ抗体
EP4534562A1 (en) Bispecific antibody and application thereof
JP2021525806A5 (enExample)
JP2024537323A5 (enExample)
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
JP2022532991A5 (enExample)
JP2025508317A5 (enExample)
JP2022512672A5 (enExample)
JP2023517794A5 (enExample)
JP2025503229A5 (enExample)